The main objective of this study is establish the performance of miR371 in management of testicular cancer
Patients with suspected testicular cancer, referred to orchiectomy.
Patients diagnosed with testicular germ cell cancer.
Age 18-70 years of age.
Must be able receive information and to consent.
Other prior or concomitant malignancy (other than testicular cancer).
Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures.
Men with suspected and confirmed testicular germ cell cancer, aged 18-70 years. Seminomas and non-seminomas, stage I-IV.
Cohort
Prospective
Biomarker analysis
Other interventionBlood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months
miR371 as a biomarker in testicular germ cell cancer at orchiectomy
To estimate the sensitivity and specificity of miR371 in identifying viable tumour cells at diagnosis
miR371 as a biomarker in testicular germ cell cancer at RPLND
To estimate the sensitivity and specificity of miR371 in identifying viable tumour cells at RPLND
miR371 as a biomarker in testicular germ cell cancer during chemotherapy treatment
To estimate the performance of miR371 in monitoring of treatment efficiency (chemotherapy)
miR371 as a biomarker in testicular germ cell cancer and detection of recurrence
To estimate the performance of miR371 in (early) detection of recurrence
Click on the lead sponsor to view all of their trials.
Haukeland University Hospital
Lead sponsor
Karolinska University Hospital
Collaborator
Sahlgrenska University Hospital
Collaborator
Helse Fonna
Collaborator
University Hospital of North Norway
Collaborator
Oslo University Hospital
Collaborator
